Avoro Capital Advisors 13F annual report
Avoro Capital Advisors is an investment fund managing more than $7.51 trillion ran by Scott Epstein. There are currently 41 companies in Mr. Epstein’s portfolio. The largest investments include United Therapeutics Corp and Madrigal Pharmaceuticals Inc, together worth $1.49 trillion.
$7.51 trillion Assets Under Management (AUM)
As of 7th August 2024, Avoro Capital Advisors’s top holding is 2,858,888 shares of United Therapeutics Corp currently worth over $911 billion and making up 12.1% of the portfolio value.
Relative to the number of outstanding shares of United Therapeutics Corp, Avoro Capital Advisors owns less than approximately 0.1% of the company.
In addition, the fund holds 2,055,555 shares of Madrigal Pharmaceuticals Inc worth $576 billion, whose value grew 11.1% in the past six months.
The third-largest holding is Ascendis Pharma worth $572 billion and the next is Argenx Se worth $533 billion, with 1,238,467 shares owned.
Currently, Avoro Capital Advisors's portfolio is worth at least $7.51 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Avoro Capital Advisors
The Avoro Capital Advisors office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Scott Epstein serves as the Chief Compliance Officer & COO at Avoro Capital Advisors.
Recent trades
In the most recent 13F filing, Avoro Capital Advisors revealed that it had opened a new position in
Bicycle Therapeutics plc and bought 700,000 shares worth $14.2 billion.
This means they effectively own approximately 0.1% of the company.
Bicycle Therapeutics plc makes up
0.3%
of the fund's Health Care sector allocation and has grown its share price by 4.8% in the past year.
The investment fund also strengthened its position in Madrigal Pharmaceuticals Inc by buying
111,111 additional shares.
This makes their stake in Madrigal Pharmaceuticals Inc total 2,055,555 shares worth $576 billion.
Madrigal Pharmaceuticals Inc soared 39.6% in the past year.
On the other hand, there are companies that Avoro Capital Advisors is getting rid of from its portfolio.
Avoro Capital Advisors closed its position in Viking Therapeutics Inc on 14th August 2024.
It sold the previously owned 3,590,000 shares for $294 billion.
Scott Epstein also disclosed a decreased stake in Sarepta Therapeutics Inc by 0.3%.
This leaves the value of the investment at $474 billion and 3,000,000 shares.
One of the largest hedge funds
The two most similar investment funds to Avoro Capital Advisors are Capital International, ca/ and Saturna Capital Corp. They manage $7.52 trillion and $7.53 trillion respectively.
Scott Epstein investment strategy
Avoro Capital Advisors’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 70.9% of
the total portfolio value.
The fund focuses on investments in the United States as
58.5% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
10% of the total holdings value.
On the other hand, large-cap stocks make up only 7.3% of the portfolio.
The average market cap of the portfolio companies is close to $2.98 billion.
The complete list of Avoro Capital Advisors trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| United Therapeutics Corp |
No change
2,858,888
|
$910,698,772,000 | 12.13% |
| Madrigal Pharmaceuticals Inc |
5.71%
2,055,555
|
$575,884,289,000 | 7.67% |
| Ascendis Pharma |
5.80%
4,196,661
|
$572,340,627,000 | 7.62% |
| Argenx Se |
No change
1,238,467
|
$532,590,349,000 | 7.09% |
| Sarepta Therapeutics Inc |
30.95%
3,000,000
|
$474,000,000,000 | 6.31% |
| Krystal Biotech Inc |
4.80%
2,433,000
|
$446,796,120,000 | 5.95% |
| Apellis Pharmaceuticals Inc |
No change
11,111,111
|
$426,222,218,000 | 5.68% |
| Biomarin Pharmaceutical Inc. |
4.41%
4,557,416
|
$375,212,059,000 | 5.00% |
| Cerevel Therapeutics Hldng |
0.21%
7,539,547
|
$308,292,077,000 | 4.11% |
| Viking Therapeutics Inc |
Closed
3,590,000
|
$294,380,000,000 | |
| Spdr Series Trust - S&p Biotech |
29.42%
3,035,000
|
$281,374,850,000 | 3.75% |
| Amicus Therapeutics Inc |
No change
27,400,000
|
$271,808,000,000 | 3.62% |
| Avidity Biosciences, Inc. |
11.67%
6,505,000
|
$265,729,250,000 | 3.54% |
| Arrowhead Pharmaceuticals Inc. |
3.90%
8,888,888
|
$231,022,199,000 | 3.08% |
| Alpine Immune Sciences Inc |
Closed
5,775,000
|
$228,921,000,000 | |
| Xenon Pharmaceuticals Inc |
No change
5,666,666
|
$220,943,307,000 | 2.94% |
| Intra-Cellular Therapies Inc |
21.21%
3,000,000
|
$205,470,000,000 | 2.74% |
| Vera Therapeutics Inc |
18.15%
4,309,590
|
$155,920,966,000 | 2.08% |
| Moonlake Immunotherapeutics |
7.36%
2,770,000
|
$121,796,900,000 | 1.62% |
| Kymera Therapeutics, Inc. |
No change
3,888,888
|
$116,083,307,000 | 1.55% |
| Alnylam Pharmceuticals Inc. |
33.33%
400,000
|
$97,200,000,000 | 1.29% |
| Iovance Biotherapeutics Inc |
No change
11,700,000
|
$93,834,000,000 | 1.25% |
| Macrogenics Inc |
Closed
6,150,000
|
$90,528,000,000 | |
| Soleno Therapeutics Inc |
28.72%
2,091,666
|
$85,339,973,000 | 1.14% |
| Merus N.V |
52.44%
1,355,000
|
$80,175,350,000 | 1.07% |
| Syndax Pharmaceuticals Inc |
7.91%
3,888,437
|
$79,829,612,000 | 1.06% |
| Biocryst Pharmaceuticals Inc. |
3.68%
12,570,000
|
$77,682,600,000 | 1.03% |
| Kura Oncology Inc |
8.01%
3,541,505
|
$72,919,588,000 | 0.97% |
| Ocular Therapeutix Inc |
12.74%
8,060,000
|
$55,130,400,000 | 0.73% |
| Roivant Sciences Ltd |
Closed
4,651,162
|
$49,023,247,000 | |
| Mannkind Corp |
2.67%
8,759,524
|
$45,724,715,000 | 0.61% |
| Vaxcyte, Inc. |
No change
575,000
|
$43,418,250,000 | 0.58% |
| Spyre Therapeutics Inc |
No change
1,839,138
|
$43,238,134,000 | 0.58% |
| Autolus Therapeutics plc |
No change
12,345,678
|
$42,962,959,000 | 0.57% |
| Taysha Gene Therapies, Inc. |
No change
18,650,000
|
$41,776,000,000 | 0.56% |
| Marinus Pharmaceuticals Inc |
Closed
4,140,607
|
$37,431,087,000 | |
| Ultragenyx Pharmaceutical Inc. |
No change
830,000
|
$34,113,000,000 | 0.45% |
| Rocket Pharmaceuticals Inc |
Closed
1,260,900
|
$33,968,646,000 | |
| Verrica Pharmaceuticals Inc |
No change
3,999,999
|
$29,159,993,000 | 0.39% |
| CRISPR Therapeutics AG |
Closed
419,580
|
$28,598,573,000 | |
| Tourmaline Bio Inc |
No change
2,222,222
|
$28,577,775,000 | 0.38% |
| Cg Oncology Inc |
No change
700,000
|
$22,099,000,000 | 0.29% |
| Monte Rosa Therapeutics Inc |
No change
4,535,000
|
$16,960,900,000 | 0.23% |
| Bicycle Therapeutics plc |
Opened
700,000
|
$14,168,000,000 | 0.19% |
| Kyverna Therapeutics Inc |
Closed
475,000
|
$11,799,000,000 | |
| Aadi Biosciences Inc |
No change
2,849,402
|
$4,160,127,000 | 0.06% |
| Dyne Therapeutics, Inc. |
Opened
115,751
|
$4,084,853,000 | 0.05% |
| Adverum Biotechnologies Inc |
No change
416,666
|
$2,858,329,000 | 0.04% |
| Neurogene Inc |
Opened
22,029
|
$801,635,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 49 holdings | |||
Hedge funds similar to Avoro Capital Advisors
- Greenhaven Associates Inc
- Tortoise Capital Advisors, L.L.C
- Synovus Financial Corp
- Rwa Wealth Partners
- Everett Harris & Co ca/
- Saturna Capital Corp
- Capital International, ca/
- Mirova Us
- Artemis Investment Management LL.P.
- Matrix Capital Management , L.P.
- Riverbridge Partners
- Blue Trust
- Comgest Global Investors S.a.s
- First Pacific Advisors, L.P.